Background Due to the high prevalence of resistance to NNRTI-based ART since 2018,
consolidated recommendations from the WHO have indicated dolutegravir as the preferred …

In sub-Saharan Africa (SSA) the burden of non-nucleoside reverse transcriptase inhibitor
(NNRTI) HIV drug resistance (HIVDR) has been high over the years. Therefore, in 2018 the …

Dolutegravir-based antiretroviral therapy (ART) has been scaled up in many developing
countries, including Ethiopia. However, subtype-dependent polymorphic differences might …

To ensure optimal prescribing practices in the dolutegravir-era in Cameroon, we compared
first-line virological response (VR) under tenofovir+ lamivudine+ dolutegravir (TLD) …

Integrase strand transfer inhibitor (INSTI)-containing regimens in HIV-1-infected patients
have experienced a global increase. Recently, WHO has emphasized the need to fast-track …

Increased HIV drug resistance (HIVDR) with antiretroviral therapy (ART) rollout may
jeopardize therapeutic options, especially in this era of transition to fixed-dose tenofovir …

The efficacy of first-line antiretroviral therapy (ART) may be hampered by the presence of
HIV drug resistance (HIVDR). We described HIV-1 pre-treatment drug resistance (PDR) …

As sub-Saharan Africa (SSA) countries are transitioning to dolutegravir (DTG)-based ART,
baseline data are required for optimal monitoring of therapeutic response. In this frame, we …

The growing emergence of non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV drug
resistance in sub-Saharan Africa (SSA) led to the World Health Organization (WHO) …

Drug regimens containing integrase strand transfer inhibitors (INSTIs) are widely
recommended by international guidelines for ART-naive people living with HIV (PLWH). 1, 2 …